This post was originally published on this site
The single-dose J&J (NYSE:JNJ) shot, once touted as an important tool for vaccinating people living in hard-to-reach areas, has been behind its schedule for deliveries in the United States and Europe.
The drugmaker last year faced quality problems at a Baltimore manufacturing facility, resulting in wastage of millions of doses.
The forecast comes at a time when the company looks to separate its consumer health unit and focus on its medical devices and pharmaceuticals businesses.
